Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial | Zendy

James A. deLemos | Zendy; Michael A. Blazing | Zendy; Stephen D. Wiviott | Zendy; William J. Brady | Zendy; Harry C. White | Zendy; Keith A.A. Fox | Zendy; Joanne Palmisano | Zendy; Karen E. Ramsey | Zendy; David W. Bilheimer | Zendy; Elfed Lewis | Zendy

Open Access

Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial

Author(s) -

James A. deLemos,

Michael A. Blazing,

Stephen D. Wiviott,

William J. Brady,

Harry C. White,

Keith A.A. Fox,

Joanne Palmisano,

Karen E. Ramsey,

David W. Bilheimer,

Elfed Lewis

Publication year - 2004

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1016/j.ehj.2004.06.028

Subject(s) - medicine , tirofiban , timi , acute coronary syndrome , aspirin , clinical endpoint , st elevation , population , conventional pci , myocardial infarction , randomized controlled trial , surgery , environmental health

In high risk patients with non-ST elevation acute coronary syndromes (ACS), enoxaparin is generally preferred to unfractionated heparin (UFH). However, less is known about the relative merits of these two forms of heparin in patients receiving concomitant glycoprotein IIb/IIIa inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research